UK markets open in 7 hours 11 minutes

Akebia Therapeutics, Inc. (AKBA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.6700-0.1200 (-4.30%)
At close: 1:00PM EST
2.7200 +0.05 (+1.87%)
After hours: 04:17PM EST
Sign in to post a message.
  • l
    We are heading north from here.
    All indications are that VAD is going to be approved in late least for CKD dialysis patients.
    We are at $2.74 and there is not too much push down any longer. Speculative buyers are going to want to start buying into the risk profile here realizing that the upside may be a double or triple just BEFORE the FDA decision. It does not make much sense to be wanting to short at this point knowing your upside maybe be a $1.00 if not approved, but your risk of loss is infinite if it IS approved. This will move up to about $6.00 is my guess by March, then there will be some that get out before PUDFA. I have got my position full and we wait to after decision in March. My guess is $10+ afterwards and if NDD is approved then $15 plus.
  • E
    Happy Thanksgiving, Merry Christmas, and Happy New Year all longs... catch up in the New Year when the count down to the only date that matters for shareholders of AKBA begins in earnest.
  • m
    AKBA seems to lost its lustrous appeal among the retail investors amid mgt's below average performance in many occassisons and hence the discounted SP at this level. Looking at 2022 1st qtr . PDUFA date the SP should go up but not as much due to overall gloomy market condition. Lets hope for a timely approval of VAD which is long due for small investors like us.
  • G
    Bought 4 k more. I’ve 25 calls @2 expiring this week.

    Total 11.5 k in all.

    Will wait for approval!

  • D
    A few highlights:

    —FDA completed mid cycle review without any issues
    —market share of vafseo growing in Japan
    —they are “very confident “ data support approval in DD-CKD
    —data shows gradual, steady increases in hemoglobin while minimizing overshoots
    —there is no increase in blood clots, seizures or infections ( the main problems with roxadustat)
    —$2 billion market in US alone
    —they believe US data supports approval for NDD-CKD as well
    —when hemoglobin 10-11 target, hazard ratio 1.01, clearly no increase in risk
    —they believe the FDA recognizes an unmet need and that the benefits outweigh risks in NDD-CKD
    —FDA messaging to them has been consistent: there will not be an adcom panel
    —milestone payments: $15 million for dialysis approval, $50 million for NDD, $25 million on TDAPA approval, $17 million for Europe approval
    —current market valuation doesn’t reflect an expectation of FDA approval at all, they reiterated that they do expect approval for at least dialysis, possibly NDD too.
    —they intentionally have 2 suppliers so there will be adequate supply for quick ramp up
  • C
    I See Vadadustat UT,,, Covid Trial is now Increased to From 250 ,,To 400 Now ,,, 650,,, With Co Sponsor Akebia & Dept of Defense ,,,Happy Thanksgiving Longs ~O~
  • A
    TSLA CEO works 16 hours a day nonstop .I doubt it ours works 16 hours a year .
    And some CEO,s they are on hibernation
  • g
    I listened to the presentation on the website. It was dry but presenting a lot of information. AKBA is in the middle of a study now to test the effectiveness of VAD using a three times a week dosage. They think that this will be a way to market to dialysis centers since patients typically go to dialysis three times a week and this will also ensure compliance with the dosing. Interesting. Of course it’s going to mean more money spent on trials and of course it will require FDA approval which God knows how long that’s gonna take if the results are positive.
  • S
    Finally some positive action from the Wainwright upgrade. Now we just need some insider buys to really take off and sustain this uptrend.
  • R
    H. C. Wainwright adjusts AKBA price to $10 from $6 and keeps a BUY rating.
  • A
    Never invest in a stock that big bosses survives from investors money
  • J
    Quiet board huh! Things are looking great again amigos…if you don’t believe me ask Doc and Dutch
  • S
    Second straight green day for AKBA. May not seem like much, but it's the first time it has happened in the last 15 trading sessions. Agree with @longy's post, I think the bottom is in for all intents and purposes here and we'll be moving higher. Seasonal tailwinds are with us in late Dec and Jan, and this one may make a lot of "stocks you should buy" lists. GL!
  • R
    Something tells me they are announcing a capital raise tomorrow. Had to keep this awful news separate from their awful earnings. They are not even growing their products in the market. Butler needs to go. Send email to investor relations.
  • M
    it's a while now that we see price prediction of 40-50$ ... by some people.
    it's verry quit here .... so everyone merry Christmas and a happy richfull 2022 !! ;-)
  • A
    The impact of anemia on all patients with CKD is significant. We believe in the potential of vadadustat to help these patients. With US approval, we'll have the potential to address the unmet needs of over 0.5 million adult patients on dialysis and rapidly establish vadadustat as the new oral standard of care for the treatment of anemia due to CKD. That represents a potential $2 billion market opportunity in the US alone.
  • L
    CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare.
  • N
    Has no one wondered why the CC is tomorrow and wasn't on Thursday when the results have been released....?
  • G
    Slow and steady accumulation for approval!

  • B
    H.C Wainwright Adjusted PT o $10. Log term buy here.